Saturday 17 October 2026
Export CRDL’s income statement to Excel — free account
Cardiol Therapeutics Inc.
CRDL Healthcare Drug Manufacturers Specialty & Generic
In the quarter to June 2026, EPS grew 42.9%, free cash flow grew 10.6% and total debt fell 38.8%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
1.10
0.05
−4.35%
Follow CRDL
Cardiol Therapeutics Inc. (CRDL) P/E ratio
Cardiol Therapeutics Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 0.0× (October 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2021 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2021 | 0.0× | — |
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| CPIX Cumberland Pharmaceuticals Inc. compare | n/m |
| DERM Journey Medical Corporation compare | n/m |
| CLVR Clever Leaves Holdings Inc. compare | n/m |
| ORGO Organogenesis compare | n/m |
| CRDL Cardiol Therapeutics Inc. | n/m |
| AKBA Akebia Therapeutics, Inc. compare | n/m |
| PROCF Sofgen Pharma S.A compare | 0.1× |
| OGI Organigram Global Inc. compare | 2.0× |
| BGM BGM Group Ltd. compare | 144× |
| Drug Manufacturers Specialty & Generic industry median | 19.2× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)